Drug Trial Radar · NCT04204473
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
May 7, 2020
Primary completion
Mar 3, 2023
Study completion May 18, 2023
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of TY-9591, with dose-escalation stage and dose-expansion stage.
Conditions
- NSCLC
Interventions
TY-9591(10mg,40mg) qd. poDrug
Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: First 29 days of dosing
- Maximum Tolerated Dose (MTD)Time frame: 1year
- Recommended Phase 2 dose (RP2D)Time frame: through study completion, an average of 2.5 years
- Overall Response Rate (ORR)Time frame: At least 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.